Lipoprotein(a)—The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation

por Ugovšek, Sabina, Šebeštjen, Miran
Publicado 2021

Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall

por Ugovšek, Sabina, Šebeštjen, Miran
Publicado 2022

PCSK9 as an Atherothrombotic Risk Factor

por Sotler, Tadeja, Šebeštjen, Miran
Publicado 2023

Predictors of functional and morphological arterial wall properties in coronary artery disease patients with increased lipoprotein (a) levels before and after treatment with propro...

por Likozar, Andreja Rehberger, Šebeštjen, Miran
Publicado 2023

Smoking and diabetes attenuate beneficial effects of PSCK9 inhibitors on arterial wall properties in patients with very high lipoprotein (a) levels

por Rehberger Likozar, Andreja, Šebeštjen, Miran
Publicado 2022

Influence of lipid-lowering drugs on inflammation: what is yet to be done?

por Ugovšek, Sabina, Zupan, Janja, Rehberger Likozar, Andreja, Šebeštjen, Miran
Publicado 2021

Gene Expression Profiling of Markers of Inflammation, Angiogenesis, Coagulation and Fibrinolysis in Patients with Coronary Artery Disease with Very High Lipoprotein(a) Levels Treat...

por Hrovat, Katja, Rehberger Likozar, Andreja, Zupan, Janja, Šebeštjen, Miran
Publicado 2022

Atherosclerotic Cardiovascular Disease: Risk Assessment, Prevention and Treatment Strategies

por Jeras, Jernej, Ugovšek, Sabina, Rehberger Likozar, Andreja, Šebeštjen, Miran
Publicado 2022

Smoking and Diabetes Attenuate Number of CD34(+) Haematopoietic Stem Cells in Peripheral Blood of Patients with Advanced Peripheral Artery Disease

por Sernek, Barbara, Kamnikar, Rok, Sebestjen, Miran, Boc, Anja, Boc, Vinko
Publicado 2023

LPA Genotypes and Haplotypes Are Associated with Lipoprotein(a) Levels but Not Arterial Wall Properties in Stable Post-Coronary Event Patients with Very High Lipoprotein(a) Levels

por Rehberger Likozar, Andreja, Blinc, Aleš, Trebušak Podkrajšek, Katarina, Šebeštjen, Miran
Publicado 2021

Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibito...

por Levstek, Tina, Karun, Tina, Rehberger Likozar, Andreja, Šebeštjen, Miran, Trebušak Podkrajšek, Katarina
Publicado 2023

The Influence of Treatment with PCSK9 Inhibitors and Variants in the CRP (rs1800947), TNFA (rs1800629), and IL6 (rs1800795) Genes on the Corresponding Inflammatory Markers in Patie...

por Levstek, Tina, Podkrajšek, Nik, Rehberger Likozar, Andreja, Šebeštjen, Miran, Trebušak Podkrajšek, Katarina
Publicado 2022

TNF-α Predicts Endothelial Function and Number of CD34(+) Cells after Stimulation with G-CSF in Patients with Advanced Heart Failure

por Ugovšek, Sabina, Rehberger Likozar, Andreja, Finderle, Sanjo, Poglajen, Gregor, Okrajšek, Renata, Vrtovec, Bojan, Šebeštjen, Miran
Publicado 2022

Long-Term Effects of Angiotensin Receptor–Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction

por Poglajen, Gregor, Anžič-Drofenik, Ajda, Zemljič, Gregor, Frljak, Sabina, Cerar, Andraž, Okrajšek, Renata, Šebeštjen, Miran, Vrtovec, Bojan
Publicado 2020

Pharmacologic modulation of intracellular Na(+) concentration with ranolazine impacts inflammatory response in humans and mice

por Lenz, Max, Salzmann, Manuel, Ciotu, Cosmin I., Kaun, Christoph, Krychtiuk, Konstantin A., Rehberger Likozar, Andreja, Sebestjen, Miran, Goederle, Laura, Rauscher, Sabine, Krivaja, Zoriza, Binder, Christoph J., Huber, Kurt, Hengstenberg, Christian, Podesser, Bruno K., Fischer, Michael J. M., Wojta, Johann, Hohensinner, Philipp J., Speidl, Walter S.
Publicado 2022